Abstract: We investigated whether midlife pulse pressure is associated with brain atrophy and cognitive decline, and whether the association was modified by apolipoprotein-E E4 (APOE-E4) and hypertension. Participants (549 stroke-free and dementia-free Framingham Offspring Cohort Study participants, age range = 55.0 to 64.9 y) underwent baseline neuropsychological and magnetic resonance imaging (subset, n = 454) evaluations with 5-to 7-year follow-up. Regression analyses investigated associations between baseline pulse pressure (systolicÀ diastolic pressure) and cognition, total cerebral volume and temporal horn ventricular volume (as an index of smaller hippocampal volume) at follow-up, and longitudinal change in these measures. Interactions with APOE-E4 and hypertension were assessed. Covariates included age, sex, education, assessment interval, and interim stroke. In the total sample, baseline pulse pressure was associated with worse executive ability, lower total cerebral volume, and greater temporal horn ventricular volume 5 to 7 years later, and longitudinal decline in executive ability and increase in temporal horn ventricular volume. Among APOE-E4 carriers only, baseline pulse pressure was associated with longitudinal decline in visuospatial organization. Findings indicate arterial stiffening, indexed by pulse pressure, may play a role in early cognitive decline and brain atrophy in mid to late life, particularly among APOE-E4 carriers.
S ubstantial evidence suggests that midlife vascular risk factors, including hypertension, convey increased risk of later cognitive decline and dementia, independent of stroke, [1] [2] [3] and that these associations may be strengthened by the presence of the apolipoprotein-E E4 allele (APOE-E4). 4 Beyond these traditional vascular risk factors, agerelated arterial stiffening, quantified by brachial artery pulse pressure, central pulse pressure, or carotid-femoral pulse wave velocity, has also been linked to cerebral atrophy, 5 cognitive decline, 6, 7 and dementia. 8, 9 Similar to traditional vascular risk factors, evidence suggests that the relationship between pulse pressure and cognitive decline may be modified by APOE genotype, potentially indicating an interactive effect on genetic risk for Alzheimer disease (AD). 10 Additional studies indicate that arterial stiffening may potentiate cerebral small vessel disease, 5 particularly in those with hypertension. 11, 12 Thus, mounting evidence suggests that arterial stiffening may be an important component of the vascular contribution to dementia through its impact on brain atrophy and cerebrovascular disease, as well as interactions with other genetic and vascular risk factors for dementia.
Importantly, age-related arterial stiffening is also thought to be independent of traditional vascular risk factors, and may convey added risk of end-organ damage even in the absence of other health concerns. 13 This is consistent with the hypothesis that these stiffening changes may play a role in the increased risk of dementia with age. 14 In a series of recent studies, markers of arterial stiffening have demonstrated relationships with cerebral spinal fluid biomarkers of cerebral amyloidosis and tau-mediated neurodegeneration, 9, 15 as well as cerebral amyloid retention on positron emission tomography. [15] [16] [17] Some evidence further suggests that the relationship between arterial stiffening and cerebral amyloid retention may be particularly salient in carriers of the APOE-E4 allele. 18 These findings suggest that arterial stiffening may contribute to AD pathophysiology, in addition to cerebrovascular disease, which may underlie the predictive utility of arterial stiffening in age-related cognitive decline.
To further evaluate the role of arterial stiffening in cognitive and brain aging, the current study investigated whether brachial artery pulse pressure, a simple and clinically available index of arterial stiffness, was predictive of cognitive and atrophic brain changes over a 5-to 7-year period. This longitudinal study focused on a subset of the Framingham Offspring Cohort with relatively few health concerns, during the transition from mid to late life (aged 55 to 64 y at baseline), with the aim of providing information on early cognitive and brain changes potentially indicative of future dementia risk. The study also examined interactions with genetic risk for AD, by investigating the potential role of the APOE-E4 in modifying the predictive value of baseline pulse pressure. It was hypothesized that pulse pressure would predict cerebral and hippocampal atrophy, and neuropsychological decline, even in the absence of any evidence of subcortical ischemic white matter disease. It was further hypothesized that these changes would be more prominent in those carrying the APOE-E4 allele.
METHODS

Participants and Procedures
The Framingham Heart Study is a community-based, prospective study aimed at identifying risk factors for cardiovascular disease. Participants in the current study were a subset of the Offspring Cohort who were of older middle age at baseline (55 to 64 y) and in good health. Participants underwent health examination between 1998 and 2001, and 2 neuropsychological assessments Z5 years apart (first assessment, 1999 to 2003, and second assessment, 2004 to 2009). Three blood pressure measures were obtained within a 15-to 20-minute time period (twice from the left arm and once from the right arm) during the health examination. These were averaged to obtain systolic and diastolic blood pressure estimates, and pulse pressure was calculated as the difference between these measures (systolic Àdiastolic pressure). Hypertension was defined as systolic blood pressure of Z140 mm Hg, diastolic blood pressure of Z90 mm Hg, or use of antihypertensive medications. 19 Participants were classified into 3 blood pressure groups: normal [systolic blood pressure (SBP) < 120 mm Hg and diastolic blood pressure (DBP) < 80 mm Hg], prehypertension (SBP = 120 to 139 mm Hg or DBP = 80 to 89 mm Hg), and hypertensive (SBPZ140 mm Hg or DBPZ90 mm Hg or antihypertensive treatment). Those in the normal or prehypertension groups were not taking antihypertensive medications. Among 1242 participants aged 55 to 64 years who were examined, the following exclusions were made: prevalent clinical stroke (n = 8), prevalent dementia (n = 0), missing blood pressure (n = 3), missing neuropsychological assessment (n = 665), <5-year interval between neuropsychological assessments (n = 8), missing APOE status (n = 13), and other neurological conditions that could impact cognitive test scores (n = 18). No participants were demented. Final total sample was 549 participants. A subset of 454 participants also underwent brain magnetic resonance imaging (MRI) concurrent with baseline and follow-up neuropsychological evaluations. 
Neuropsychological Assessment
MRI and Neuroanatomic Regions of Interest
The MRI techniques used in the Framingham Heart Study Offspring Study have been described previously. 23 Briefly, participants were scanned on a 1.5-T Siemens Magnetom. All images were read by individuals who were blinded to any demographic or clinical information including age and parental dementia status. From T1-weighted scans, we computed total cerebral brain volume (TCBV) and the volume around the temporal horns [temporal horn volume (THV)], which served as a surrogate measure of hippocampal volume with greater THV being proportional to smaller hippocampal volume. 23 T2-weighted double-spin echo coronal sequences were also acquired in 4-mm contiguous slices and used to quantify total white matter hyperintensity volume (WMHV). All volumetric measures were calculated as a percentage of total cranial volume to correct for differences in head size. 24 
Statistical Analyses
Outcome variables were natural log (ln) transformed to improve normality, as needed. Annualized raw change on neuropsychological and MRI measures was calculated as follows: [(score at the second assessment minus score at the first assessment)/(time between the first and second assessments in years)]. Signs of Trail Making Test variables were reversed during calculation of annual rate of change to be consistent with the other neuropsychological measures (ie, negative rate of change indicates decline).
Multivariable linear regression models were constructed to examine the association between baseline pulse pressure and brain volume and performance on neuropsychological tests 5 to 7 years later, as well as annualized change in brain volume (TCBV and THV), WMHV, and neuropsychological performance. All analyses were adjusted for age at blood pressure measurement, sex, education group (< high school degree, high school degree, some college, Zcollege degree), and time (y) from blood pressure assessment to the first neuropsychological assessment. b-coefficients from the linear regression models represent the effect on neuropsychological measures or percent brain volume per mm Hg of pulse pressure after covariate adjustment. Interactions with APOE-E4 carrier status and blood pressure were also evaluated by the inclusion of a cross-product term in the model. A P-value of <0.05 was considered statistically significant for main effects. Stratified analysis results were presented for all instances where the P-value for interaction was <0.05. Given the exploratory nature of the study, correction for multiple comparisons was not applied. All analyses were performed using SAS version 9.4 (Cary, NC). Table 1 presents baseline characteristics of the sample participants at the time baseline pulse pressure was measured. Characteristics of participants who were not included All models are adjusted for age at pulse pressure measurement, sex, education group, years between pulse pressure measurement and follow-up neurospsychological testing, and prevalent stroke at follow-up neurospsychological testing. Trail A, Trails B-A, HVOT, and BNT raw scores were transformed using natural log. Signs were inverted for Trail A and Trails B-A so that the direction of effects is consistent across all measures.
RESULTS
* All models are adjusted for age at pulse pressure measurement, sex, education group, and years between pulse pressure measurement and follow-up neuropsychological testing. There was insufficient sample size in the stratified analysis to adjust for prevalent stroke at follow-up neuropsychological testing.
APOE-E4 indicates apolipoprotein-E E4; HVOT, Hooper Visual Organization Test.
in the study sample due to lack of neuropsychological testing are presented in Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/WAD/ A122. Overall, participants who were excluded from the study sample had lower education levels, higher pulse pressure, and a higher prevalence of hypertension.
Neuropsychological Test Outcomes
Across all participants, higher baseline pulse pressure was associated with worse performance on a test of executive functioning (Trails B-A) at 5-to 7-year follow-up, P = 0.02 (Table 2) , as well as greater annualized decline in performance on this test over the follow-up interval, P = 0.03 (Table 2 ). There were no statistically significant interactions between pulse pressure and blood pressure group for any of the neuropsychological test outcomes.
Regarding APOE-E4 carrier status, interaction analyses suggested potential differences in the relationship between pulse pressure and longitudinal change in visuospatial organization over the follow-up interval (HVOT; Table 3 ). Stratified analyses indicated that among APOE-E4 carriers, higher baseline pulse pressure was associated with greater decline in visuospatial organization ability over follow-up, b = À 0.006, P = 0.02 (Fig. 1) .
MRI Brain Outcomes
Higher baseline pulse pressure was associated with smaller TCBV, P = 0.01, and larger THV (indexing smaller hippocampal volume), P = 0.01, at follow-up (Table 4) , as well as greater increase in THV over the follow-up interval, P = 0.03 (Table 4 ). There were no statistically significant interactions between pulse pressure and either hypertensive status or APOE-E4 carrier status for any MRI measure (Table 4) . Participants showed little white matter disease on MRI at follow-up (median = 0.081%, 25th percentile = 0.044%, 75th percentile = 0.16%) and pulse pressure was not associated with total WMHV in any analyses (all P > 0.05).
DISCUSSION
We hypothesized that arterial stiffening, indexed by higher pulse pressure, may accelerate cognitive decline in middle-aged to young-old adults, and that this effect may be further potentiated by the presence of hypertension and the APOE-E4 allele. Consistent with this hypothesis, the present study's findings indicated that increased pulse pressure during the transition from middle-aged to youngold age was associated with decline on a measure of executive function, even in the absence of significant white matter lesion pathology. This finding is also consistent with extensive evidence that vascular dysfunction and disease impacts executive abilities, 25, 26 and further suggests that these changes may be independent of subcortical small vessel disease observable on MRI. 27 Executive abilities show expected declines as part of "normal" cognitive aging. 22, 28 The results of the present study could also suggest that these declines may occur in part due to agerelated arterial stiffening and its hemodynamic consequences. Importantly, findings were significant even after controlling for age, suggesting that arterial stiffness may also further contribute to executive decline beyond that observed as part of normal aging. The current study further revealed that participants at genetic risk for AD due to presence of the APOE-E4 allele displayed additional relationships between pulse pressure and visuospatial organization. Our test of visuospatial organization, the HVOT, assesses primarily executive and visuospatial domains, requiring mental rotation and reconstruction of disassembled line drawings, but also requires naming ability. 20, 22 Thus, it remains unclear exactly which of these abilities was most related to pulse pressure, but the involvement of both visual memory and visuospatial organization may suggest that arterial stiffening has broader implications for cognitive decline among APOE-E4 carriers than noncarriers. This is consistent with a growing body of research suggesting that vascular vulnerability factors may interact with genetic risk related to APOE-E4 in conveying increased risk of cognitive decline. 4 Pulse pressure was not associated with white matter hyperintensities in this stroke-free sample with relatively low vascular risk factor burden, suggesting that relationships with cognitive decline were not due solely to observable cerebrovascular disease. Higher baseline pulse pressure was associated with smaller cerebral volume and was predictive of hippocampal atrophy, indexed by increased ventricular volume in the temporal horn. Together, these findings could point to a neurodegenerative mechanism linking pulse pressure to cognitive decline. This is consistent with prior work demonstrating associations between pulse pressure elevation and both cerebral amyloidosis 29 and taumediated neurodegeneration, 9,15 and other findings indicating that arterial stiffening predicts longitudinal change in cerebral amyloid retention. 16, 17 We hypothesize that arterial stiffening may accelerate cognitive decline, particularly among carriers of the APOE-E4 allele.
The observed relationships between pulse pressure and indicators of cognitive decline and brain atrophy may have treatment implications. Studies investigating the influence of antihypertensive medications on cognitive decline and brain atrophy have yielded mixed results. [30] [31] [32] This may be due to the great variety of available medications which work through several distinct physiological pathways. Some antihypertensive medicines exhibit "destiffening effects" that can reduce indicators of arterial stiffening independent of their effects on systolic, diastolic, and mean pressures. 33 Among these destiffening medicines, those impacting the renin angiotensin system, particularly angiotensin II AT 1 -receptor blockers, have also shown benefit for cognitive decline. 34 Thus, use of angiotensin II AT 1 -receptor blockers or other destiffening medications may exert potential benefits partly through modification of arterial stiffening and its hemodynamic consequences.
Strengths of the current study include its longitudinal design and inclusion of both neuropsychological and MRI measures in a large sample of community-dwelling adults transitioning from midlife to young-old age. Although the study findings indicated a small effect size, this may largely be because of the fact that participants were relatively healthy with very limited vascular risk and cerebrovascular disease burden. Indeed these aspects of our study sample underscore the potential importance of arterial stiffness in the slow, insidious process of cognitive and brain aging, even in the context of relatively good cognitive and cerebrovascular health. The large sample size also allowed investigation of important interaction effects for APOE-E4 carrier status and history of hypertension. Study limitations include the lack of molecular markers for neurodegenerative disease. In addition, given the exploratory nature of the study, correction for multiple comparisons was not applied. Moreover, as the study sample was predominantly white coupled with an age range of 55 to 64 years, the generalizability of our results to other populations is uncertain. Future studies should seek to replicate these findings in more diverse samples. Future studies should also further elucidate the mechanisms linking increased pulse pressure to later cognitive decline and cerebral atrophy.
